<table id="table21" width="90%" xmlns="urn:hl7-org:v3" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<caption>Table 21: Summary of the Effect of Posaconazole on Coadministered Drugs in Healthy Volunteers and Patients</caption>
<col align="left" valign="top" width="17%"></col>
<col align="left" valign="top" width="23%"></col>
<col align="left" valign="top" width="25%"></col>
<col align="center" valign="top" width="17%"></col>
<col align="center" valign="top" width="18%"></col>
<thead>
<tr stylecode="Botrule">
<th align="center" rowspan="2" stylecode="Lrule Rrule" valign="bottom">Coadministered Drug<br/>(Postulated Mechanism of Interaction is Inhibition of CYP3A4 by posaconazole)</th>
<th align="center" rowspan="2" stylecode="Rrule" valign="bottom">Coadministered Drug Dose/Schedule</th>
<th align="center" rowspan="2" stylecode="Rrule" valign="bottom">Posaconazole Dose/Schedule</th>
<th align="center" colspan="2" stylecode="Rrule" valign="bottom">Effect on Bioavailability of Coadministered Drugs</th>
</tr>
<tr>
<th align="center" stylecode="Rrule" valign="bottom">Change in Mean C<sub>max</sub>
<br/>(ratio estimate<footnote id="t20f1">Ratio Estimate is the ratio of coadministered drug plus posaconazole to coadministered drug alone for C<sub>max</sub> or AUC.</footnote>; 90% CI of the ratio estimate)</th>
<th align="center" stylecode="Rrule" valign="bottom">Change in Mean AUC<br/>(ratio estimate<footnoteref idref="t20f1"></footnoteref>; 90% CI of the ratio estimate)</th>
</tr>
</thead>
<tbody>
<tr stylecode="Botrule">
<td stylecode="Lrule Rrule">Sirolimus</td>
<td stylecode="Rrule">2-mg single oral dose</td>
<td stylecode="Rrule">400 mg (oral suspension) BID × 16 days</td>
<td stylecode="Rrule">↑ 572%<br/>(6.72; 5.62-8.03)</td>
<td stylecode="Rrule">↑ 788%<br/>(8.88; 7.26-10.9)</td>
</tr>
<tr stylecode="Botrule">
<td stylecode="Lrule Rrule">Cyclosporine</td>
<td stylecode="Rrule">Stable maintenance dose in heart transplant recipients</td>
<td stylecode="Rrule">200 mg (tablets) QD × 10 days<footnote id="t20f2">The tablet refers to a non-commercial tablet formulation without polymer.</footnote>
</td>
<td colspan="2" stylecode="Rrule">↑ cyclosporine whole blood trough concentrations<br/>Cyclosporine dose reductions of up to 29% were required</td>
</tr>
<tr stylecode="Botrule">
<td stylecode="Lrule Rrule">Tacrolimus</td>
<td stylecode="Rrule">0.05-mg/kg single oral dose</td>
<td stylecode="Rrule">400 mg (oral suspension) BID × 7 days</td>
<td stylecode="Rrule">↑ 121%<br/>(2.21; 2.01-2.42)</td>
<td stylecode="Rrule">↑ 358%<br/>(4.58; 4.03-5.19)</td>
</tr>
<tr>
<td stylecode="Lrule Rrule">Simvastatin</td>
<td align="center" stylecode="Rrule">40-mg single oral dose</td>
<td align="center" stylecode="Rrule">100 mg (oral suspension) QD × 13 days</td>
<td stylecode="Rrule">Simvastatin<br/>↑ 841%<br/>(9.41, 7.13-12.44)<br/>Simvastatin Acid<br/>↑ 817%<br/>(9.17, 7.36-11.43)</td>
<td stylecode="Rrule">Simvastatin<br/>↑ 931%<br/>(10.31, 8.40-12.67)<br/>Simvastatin Acid<br/>↑634%<br/>(7.34, 5.82-9.25)</td>
</tr>
<tr stylecode="Botrule">
<td stylecode="Lrule Rrule"></td>
<td stylecode="Rrule"></td>
<td align="center" stylecode="Rrule">200 mg (oral suspension) QD × 13 days</td>
<td stylecode="Rrule">Simvastatin<br/>↑ 1041%<br/>(11.41, 7.99-16.29)<br/>Simvastatin Acid<br/>↑851%<br/>(9.51, 8.15-11.10)</td>
<td stylecode="Rrule">Simvastatin<br/>↑ 960%<br/>(10.60, 8.63-13.02)<br/>Simvastatin Acid<br/>↑748%<br/>(8.48, 7.04-10.23)</td>
</tr>
<tr>
<td stylecode="Lrule Rrule">Midazolam</td>
<td stylecode="Rrule">0.4-mg single intravenous dose<footnote id="t20f3">The mean terminal half-life of midazolam was increased from 3 hours to 7 to 11 hours during coadministration with posaconazole.</footnote>
</td>
<td stylecode="Rrule">200 mg (oral suspension) BID × 7 days</td>
<td stylecode="Rrule">↑ 30%<br/>(1.3; 1.13-1.48)</td>
<td stylecode="Rrule">↑ 362%<br/>(4.62; 4.02-5.3)</td>
</tr>
<tr>
<td stylecode="Lrule Rrule"></td>
<td stylecode="Rrule">0.4-mg single intravenous dose<footnoteref idref="t20f3"></footnoteref>
</td>
<td stylecode="Rrule">400 mg (oral suspension) BID × 7 days</td>
<td stylecode="Rrule">↑62%<br/>(1.62; 1.41-1.86)</td>
<td stylecode="Rrule">↑524%<br/>(6.24; 5.43-7.16)</td>
</tr>
<tr>
<td stylecode="Lrule Rrule"></td>
<td stylecode="Rrule">2-mg single oral dose<footnoteref idref="t20f3"></footnoteref>
</td>
<td stylecode="Rrule">200 mg (oral suspension) QD × 7 days</td>
<td stylecode="Rrule">↑ 169%<br/>(2.69; 2.46-2.93)</td>
<td stylecode="Rrule">↑ 470%<br/>(5.70; 4.82-6.74)</td>
</tr>
<tr stylecode="Botrule">
<td stylecode="Lrule Rrule"></td>
<td stylecode="Rrule">2-mg single oral dose<footnoteref idref="t20f3"></footnoteref>
</td>
<td stylecode="Rrule">400 mg (oral suspension) BID × 7 days</td>
<td stylecode="Rrule">↑ 138%<br/>(2.38; 2.13-2.66)</td>
<td stylecode="Rrule">↑ 397%<br/>(4.97; 4.46-5.54)</td>
</tr>
<tr stylecode="Botrule">
<td stylecode="Lrule Rrule">Rifabutin</td>
<td stylecode="Rrule">300 mg QD × 17 days</td>
<td stylecode="Rrule">200 mg (tablets) QD × 10 days<footnoteref idref="t20f2"></footnoteref>
</td>
<td stylecode="Rrule">↑ 31%<br/>(1.31; 1.10-1.57)</td>
<td stylecode="Rrule">↑ 72%<br/>(1.72;1.51-1.95)</td>
</tr>
<tr stylecode="Botrule">
<td stylecode="Lrule Rrule">Phenytoin</td>
<td stylecode="Rrule">200 mg QD PO × 10 days</td>
<td stylecode="Rrule">200 mg (tablets) QD × 10 days<footnoteref idref="t20f2"></footnoteref>
</td>
<td stylecode="Rrule">↑ 16%<br/>(1.16; 0.85-1.57)</td>
<td stylecode="Rrule">↑ 16%<br/>(1.16; 0.84-1.59)</td>
</tr>
<tr stylecode="Botrule">
<td stylecode="Lrule Rrule">Ritonavir</td>
<td stylecode="Rrule">100 mg QD × 14 days</td>
<td stylecode="Rrule">400 mg (oral suspension)<br/>BID × 7 days</td>
<td stylecode="Rrule">↑ 49%<br/>(1.49; 1.04-2.15)</td>
<td stylecode="Rrule">↑ 80%<br/>(1.8;1.39-2.31)</td>
</tr>
<tr>
<td stylecode="Lrule Rrule">Atazanavir</td>
<td stylecode="Rrule">300 mg QD × 14 days</td>
<td stylecode="Rrule">400 mg (oral suspension) BID × 7 days</td>
<td stylecode="Rrule">↑ 155%<br/>(2.55; 1.89-3.45)</td>
<td stylecode="Rrule">↑ 268%<br/>(3.68; 2.89-4.70)</td>
</tr>
<tr>
<td stylecode="Lrule Rrule">Atazanavir/ ritonavir boosted regimen</td>
<td stylecode="Rrule" valign="bottom">300 mg/100 mg QD × 14 days</td>
<td stylecode="Rrule" valign="bottom">400 mg (oral suspension) BID × 7 days</td>
<td stylecode="Rrule" valign="bottom">↑ 53%<br/>(1.53; 1.13-2.07)</td>
<td stylecode="Rrule" valign="bottom">↑ 146%<br/>(2.46; 1.93-3.13)</td>
</tr>
</tbody>
</table>